English
Back
Open Account
Institutional Q2 Holdings Revealed! What Is "Smart Money" Buying?
牛牛名人追蹤
joined discussion · Sep 4 11:54

Tracking Cathie Wood: Increasing position in gene-editing leader Intellia, reducing holdings in Brera Holdings

On Thursday, all three major US stock indices rose across the board. The S&P 500 closed up 1.06% at 7,747.71 points, the Nasdaq rose 1.40% to 26,584.06 points, and the Dow Jones Industrial Average gained 1.18% to 53,686.11 points. Overall market sentiment leaned optimistic, with risk assets generally benefiting.
Against this backdrop, ARK Invest's operations were slightly restrained on the day. It selectively increased holdings in core targets with long-term disruptive innovation potential, while moderately adjusting certain positions to optimize asset allocation structure.
On Thursday, all three major US stock indices rose across the board. The S&P 500 closed up 1.06% at 7,747.71 points, the Nasdaq rose 1.40% to 26,584.06 points, and the Dow Jones Industrial Average gained 1.18% to 53,686.11 points. Overall market sentiment leaned optimistic, with risk assets generally benefiting. Against this backdrop, ARK Invest's operations were slightly restrained on the day. It selectively increased holdings in core targets with long-term disruptive innovation potential, while moderately adjusting certain positions to optimize asset allocation structure. Buy Direction: Focus on precision medicine, increase exposure to core gene-editing assets $Intellia Therapeutics (NTLA.US)$ Increased holdings by 39,548 shares on the day. Intellia is one of ARK's long-term heavy-weight core targets in in vivo CRISPR gene editing. Its CRISPR/Cas9 technology platform possesses a deep moat in the field of genetic disease treatment. Adding to positions during this broader market rebound window may reflect ARK's high confidence in its pipeline progress and long-term valuation reshaping potential, indicating a tendency to actively accumulate chips in a relatively favorable market environment. Sell Direction: Position rebalancing, reducing holdings in non-core small-cap targets $Brera Holdings (SLMT.US)$ Reduced holdings by 10,853 shares on the day. Brer...
Symbols
--
--
--
Buy Direction: Focus on precision medicine and increase exposure to core assets in gene editing.
$Intellia Therapeutics (NTLA.US)$ Increased holdings by 39,548 shares on the day. Intellia is one of ARK's long-term core holdings in in vivo CRISPR gene editing. Its CRISPR/Cas9 technology platform possesses a deep moat in the treatment of genetic diseases. Adding to positions during this market rebound window may reflect ARK's high confidence in its pipeline progress and long-term valuation re-rating potential, indicating a tendency to actively accumulate筹码 (positions) in a relatively favorable market environment.
Sell Direction: Portfolio rebalancing; reduce holdings in non-core small-cap targets.
$Brera Holdings (SLMT.US)$ Reduced holdings by 10,853 shares on the day. Compared to the core "disruptive innovation" theme of ARK's flagship funds, Brera Holdings is a relatively peripheral allocation. This reduction may be related to periodic portfolio rebalancing and reallocating capital to core thematic sectors. Against the backdrop of a strengthening broader market, releasing liquidity from non-core holdings and directing it into high-conviction positions aligns with ARK's consistent portfolio management logic of "cutting the weak and keeping the strong."
When big players make a move, you get the intel instantly! Futubull’s [Smart Money Tracker] feature has been fully upgraded. Get instant alerts on portfolio adjustments by legendary investors, institutions, and politicians!
On Thursday, all three major US stock indices rose across the board. The S&P 500 closed up 1.06% at 7,747.71 points, the Nasdaq rose 1.40% to 26,584.06 points, and the Dow Jones Industrial Average gained 1.18% to 53,686.11 points. Overall market sentiment leaned optimistic, with risk assets generally benefiting. Against this backdrop, ARK Invest's operations were slightly restrained on the day. It selectively increased holdings in core targets with long-term disruptive innovation potential, while moderately adjusting certain positions to optimize asset allocation structure. Buy Direction: Focus on precision medicine, increase exposure to core gene-editing assets $Intellia Therapeutics (NTLA.US)$ Increased holdings by 39,548 shares on the day. Intellia is one of ARK's long-term heavy-weight core targets in in vivo CRISPR gene editing. Its CRISPR/Cas9 technology platform possesses a deep moat in the field of genetic disease treatment. Adding to positions during this broader market rebound window may reflect ARK's high confidence in its pipeline progress and long-term valuation reshaping potential, indicating a tendency to actively accumulate chips in a relatively favorable market environment. Sell Direction: Position rebalancing, reducing holdings in non-core small-cap targets $Brera Holdings (SLMT.US)$ Reduced holdings by 10,853 shares on the day. Brer...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
8
Lol
1
41K Views
Report
Comment (1)
Write a Comment...
1
9
2